| 翻訳と辞書 |
BioMotiv
BioMotiv is an accelerator company associated with The Harrington Project, a national initiative centered at University Hospitals of Cleveland. The company is designed to accelerate breakthrough discoveries into medicines by advancing a portfolio of novel therapeutics in all disease areas and types of therapeutics — small molecules, antibodies, proteins, cell therapies, and nucleotides – from the discovery to pre-clinical stages of development and will also consider drug re-purposing opportunities. Opportunities are sourced primarily through relationships with research institutions and disease foundations.
==History==
In response to recent decline in the number of traditional biotechnology venture capital firms,〔Forbes, Where Is Everyone? Biotech's Dwindling Number of Venture Firms, 2012-07-23 http://www.forbes.com/sites/brucebooth/2012/07/23/where-is-everyone-biotechs-dwindling-number-of-venture-firms/〕 BioMotiv utilizes an asset-centric model to in-license, fund, and manage technologies in-house.〔MedCity News, There’s a new twist to early stage drug discovery financing: technology without the team, 2012-12-04 http://medcitynews.com/2012/12/theres-a-new-twist-to-early-stage-drug-discovery-financing-its-technology-sans-the-team-video/〕 Their goal is to address the “valley of death" 〔Tech Transfer Central, Profit/non-profit partners to carry biotech innovations across valley of death, 2012-12-12 http://www.technologytransfertactics.com/content/2012/12/12/profitnon-profit-partners-to-carry-biotech-innovations-across-valley-of-death/〕 between research, discovery, and early clinical-stage drug development. Projects are advanced by the management team through clinical proof-of-concept and then out-licensed via strategic alliances with pharmaceutical companies.〔MedCity News, The biotech valley of death has become the uncrossable canyon. Here’s one innovative approach to funding, 2012-09-21 http://medcitynews.com/2012/09/the-biotech-valley-of-death-has-become-the-uncrossable-canyon-heres-one-innovative-approach-to-funding/〕
The company has raised over $70 million to date, with a goal of raising $100 million in total. Major investors include The Harrington Family, University Hospitals of Cleveland, Nationwide Mutual Insurance Company,〔Fierce Biotech, BioMotiv garners $46M for early-stage licensing deals, R&D work, 2013-08-05 http://www.fiercebiotech.com/story/biomotiv-garners-46m-early-stage-licensing-deals-rd-work/2013-08-05〕 Takeda Pharmaceutical Company,〔Fierce Biotech, Takeda pours $25M into biotech dealmaker BioMotiv, 2014-09-26 http://www.fiercebiotech.com/story/takeda-pours-25m-biotech-dealmaker-biomotiv/2014-09-26?utm_medium=nl&utm_source=internal〕 and Biogen 〔GEN News, Biogen, BioMotiv Launch Neuroscience Collaboration, 2015-09-21 http://www.genengnews.com/gen-news-highlights/biogen-biomotiv-launch-neuroscience-collaboration/81251753/〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「BioMotiv」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|